In ₹ Crore except Per Share Latest Annual	JENBURPH FY26	BPLPHARMA FY23	KPL FY24	MAKERSL FY26	Peer Average
Valuation — at last close
P/E	—	45.39×	—	—	45.39×
P/B	—	5.78×	—	◆ 2.05×	3.92×
EV/EBITDA	—	◆ 51.68×	—	156.70×	104.19×
Market Cap	—	₹1,105 Cr	—	₹112 Cr	₹608 Cr
Growth
Revenue CAGR 3Y	◆ 7.26%	—	—	5.77%	5.77% +26%
Revenue CAGR 5Y	◆ 9.07%	—	—	1.55%	1.55% +485%
Net Income CAGR 3Y	12.18%	—	—	—	—
Profitability
EBITDA Margin	◆ 23.81%	9.80%	21.69%	1.45%	10.98% +117%
Net Income Margin	◆ 20.59%	11.16%	—	-3.42%	3.87% +432%
Return on Common Equity	◆ 18.84%	13.63%	—	-3.11%	5.26% +258%
Return on Capital Employed	—	—	19.78%	—	19.78%
Return on Assets	◆ 16.45%	9.25%	—	-2.37%	3.44% +378%
Credit & Quality
Total Debt/Equity	—	◆ 0.04×	0.43×	0.05×	0.17×
Interest Coverage	—	◆ 7.10×	4.54×	-3.91×	2.58×
Scale — latest FY
Revenue / Total Income	₹169 Cr	₹218 Cr	₹307 Cr	₹50.3 Cr	₹192 Cr -12%
Net Income	₹34.7 Cr	₹24.3 Cr	—	−₹1.7 Cr	₹11.3 Cr +207%
Total Assets	₹226 Cr	₹308 Cr	₹398 Cr	₹73.5 Cr	₹260 Cr -13%
EPS	—	₹42.14	—	₹-2.91	₹19.62
Book Value per Share	—	₹330.83	—	₹92.11	₹211.47

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.